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Abstract
The introduction of Proprotein covertase subtilisin/kexin type 9 (PCSK9) inhibitors has been
heralded as a major advancement in reducing low-density lipoprotein cholesterol levels by
nearly 50%. However, concerns have been raised on the added value to the health care sys-
tem in terms of their costs and benefits. We assess the cost-effectiveness of PCSK9 inhibi-
tors based on a decision-analytic model with existing clinical evidence. The model
compares a lipid-lowering therapy based on statin plus PCSK9 inhibitor treatment with statin
treatment only (standard therapy). From health system perspective, incremental cost per
quality adjusted life years (QALYs) gained are presented. From a private payer perspective,
return-on-investment and net present values over patient lifespan are presented. At the cur-
rent annual cost of $14,000 to $15,000, PCSK9 inhibitors are not cost-effective at an incre-
mental cost of about $350,000 per QALY. Moreover, for every dollar invested in PCSK9
inhibitors, the private payer loses $1.98. Our study suggests that the annual treatment price
should be set at $4,250 at a societal willingness-to-pay of $100,000 per QALY. However, we
estimate the breakeven price for private payer is only $600 per annual treatment. At current
prices, our study suggests that PCSK9 inhibitors do not add value to the U.S. health system
and their provision is not profitable for private payers. To be the breakthrough drug in the
fight against cardiovascular disease, the current price of PCSK9 inhibitors must be reduced
by more than 70%.
Introduction
The introduction of Proprotein covertase subtilisin/kexin type 9 (PCSK9) inhibitors to the
market has been heralded a major advancement. PCSK9 inhibitors significantly reduce low-
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density lipoprotein (LDL) cholesterol levels by about 47.5 percent [1,2] with no significant
serious adverse events. Based on their efficacy and safety, the U.S. Food and Drug Adminis-
tration (FDA) recently approved evolocumab [3] and alirocumab [4], two PCSK9 inhibitor
drugs, for use in select individuals at high risk for cardiovascular disease (CVD). Although
there is strong evidence supporting the efficacy of PCSK9 inhibitors in reducing LDL choles-
terol, increasing high density lipoprotein (HDL) cholesterol, and decreasing total cholesterol
[1,5]; their efficacy in reducing cardiovascular mortality and cardiovascular events is mixed
and still inconclusive in the long-run [6]. In two open-label, randomized trials, Sabatine
et al. [5] found a nearly 56 percent relative risk reduction in cardiovascular events after 1
year of therapy with evolocumab PCSK9 inhibitor plus standard therapy (statin with or with-
out ezetimibe) in high-risk patients [5].
Despite enthusiasm regarding potential improvements in cardiovascular risk, genuine con-
cerns have been raised on the added value to the health care system in terms of their cost and
benefits [6,7]. The prices of the first two PCSK9 inhibitor drugs ranged between $14,100 and
$14,600 per year [8], which raised concerns about the cost and benefits of PCSK9 inhibitors
from the perspective of the U.S. healthcare system. In a recent economic evaluation, the Insti-
tute for Clinical and Economic Review simulated the use of the new drug among patients with
heterozygous familial hypercholesterolemia (defined as patients with very high LDL choles-
terol) and patients with atherosclerotic cardiovascular disease [9–11]. In both cases, the
authors found that PCSK9 inhibitors were not cost-effective from a health system perspective.
Contrarily, in a study by Amgen, producer of the PCSK9 inhibitor Repatha (evolocumab), the
authors found the new drug was cost-effective when it was used among patients with heterozy-
gous familial hypercholesterolemia, but not among patients with atherosclerotic cardiovascu-
lar disease [12]. In this study we use a different modelling approach to perform the cost-
effectiveness analysis (CEA) of PCSK9 inhibitors from a health system perspective. Our results
compare and shed light on the discrepancies found in the current CEA of PCSK9 literature.
However, the main contribution of our study is the additional business case analysis from
the perspective of a private insurance payer. The payer perspective is relevant for the U.S. pri-
vate, multipayer, insurance market, where return-on-investment (ROI) is an important reim-
bursement decision driver [13,14]. In contrast with national health systems where a societal
perspective would be more relevant, in the U.S. insurance market not all benefits of PCSK9
inhibitors can be accrued by individual payers. Insurance companies fail to enjoy the long-
term benefits of their investments in their beneficiaries’ health when members move to other
insurance plans [15], and limit their benefits to avoided direct medical costs and to fixed pre-
miums. Some studies have attempted to capture these characteristics by neglecting long-term
benefits. For example, budget impact analysis only captures short-term benefits to reflect pay-
er’s decision making [9–11], and observational cost analysis of preventing major adverse
CVDs only focuses on short-term available data [16]. While there is consensus that health
insurance payers put less weight to long-term health benefits, it is unrealistic to assume that
such weights are zero.
Our study addresses three questions: 1) Are PCSK9 inhibitors cost-effective from a health
system perspective? 2) Do PCKS9 inhibitors generate a positive ROI for private insurance pay-
ers? 3) At what price would PCSK9 inhibitors add a positive net benefit to the health system
and private payers? Although many therapies covered by insurance are not cost-saving, this
analysis will determine the price at which PCSK9 inhibitors would produce a positive ROI. At
or below this price, PCSK9 inhibitors would likely be integrated into clinical practice guide-
lines and become the standard prescribed treatment. Prices above this threshold would require
insurance companies to increase premiums to their members in order to recover financial
losses.
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Methods
Study Population
The model considers a hypothetical cohort of patients beginning at age 58-year followed until
death or age 100. Their baseline characteristics resemble those of the evolocumab PCSK9
inhibitor trial population [5], where about 70% were under statin treatment. In our hypotheti-
cal cohort, 52% of participants were male, 88% were currently on medication to treat high
blood pressure, 16% were smokers and 13% had diabetes. Average systolic blood pressure was
128 mm/Hg for those under any antihypertensive medication, and 133 mm/Hg for those who
were not under treatment. At baseline, the average HDL cholesterol was 51 mg/dL, LDL cho-
lesterol was 120 mg/dL and total cholesterol was 202 mg/dL. All of these parameters were
obtained from the evolocumab trial [5].
Decision-Analytic Model
We developed a Markov decision-analysis model to compare a lipid-lowering therapy based
on: A) statin plus PCSK9 inhibitor treatment, with B) statin treatment only (standard therapy).
In the model (Fig 1) patients may live a normal life under lipid-lowering treatment or may
Fig 1. Decision-analytic model describing treatment and CVD events. Treatment could be PCSK9
inhibitor or standard-therapy. MI: Myocardial Infarction. Other: Other CVD event including unstable angina,
transient ischemic attack, congestive heart failure, etc.
doi:10.1371/journal.pone.0169761.g001
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develop a myocardial infarction, stroke, or other CVD event (unstable angina, transient ische-
mic attack, congestive heart failure, etc.). After the CVD event, patients move to a post-CVD
stage that characterizes the slow transition back to normal life in terms of quality of life and
costs. Patients may remain in the post-CVD stage for up to five years. They may have a subse-
quent CVD event. They may have a CVD-related death. Patients transition among stages on a
1-year cycle, and may die for any non-CVD-related cause at any stage of the Markov model.
All simulations were performed in Microsoft Excel.
Data Sources and Parameters
The parameters used in the model for the probability of a CVD event, mortality, treatment
cost, and health utility states are presented in Table 1. Further details about the model parame-
ters and assumptions are provided in S1 Appendix.
A key parameter in the model is the annual probability of CVD events over the patient life-
span. For our baseline scenario we projected annual probabilities at age 58 and beyond using
the one year relative risk reduction from the evolocumab study [5] and the baseline survival
function from the 10-year Framingham study [17], under the assumption that the Framing-
ham survival function is proportional to the unobserved evolocumab survival function. The
one year relative risk reduction of CVD events, excluding non-CVD deaths and coronary
revascularization, was estimated at -49.2%.
Health System Perspective
A Cost-Effectiveness Analysis (CEA) was performed from a health system perspective. We
considered the cost of the lipid-lowering treatment under therapies A and B, and the avoided
healthcare costs (savings) associated with reduced future CVD events that result from lowering
LDL cholesterol levels. The quality adjusted life years (QALYs) and costs of CVD events are
presented in Table 1. QALYs were obtained from the EQ-5D index score for chronic condi-
tions in the U.S. [18] QALYs at treatment were estimated at 0.79, which corresponds to the rel-
atively symptomatic cohort of 58-year-old hypothetical patients whose baseline characteristics
resemble those of the evolocumab PCSK9 inhibitor trial population (hypertension, diabetes,
and lipoid metabolism). For the 5 years in the post-CVD event, we assume a non-linear pro-
gression from the low 25% EQ-5D QALY score to the QALY at treatment. All QALYs were
age-dependent. Costs are discussed below.
The incremental cost-effectiveness ratio (ICER) was defined as the difference between ther-
apies A and B in treatment costs less any avoided healthcare costs from CVD events divided by
the difference in QALYs between therapies A and B. This yielded the net cost per QALY
improvement for PSCK9 inhibitors compared to standard therapy. Both, costs and QALYs
were discounted at a 3% rate.
Payer Perspective
A ROI analysis was also performed from a private insurance payer perspective. Three elements
characterize this perspective. First, individual payers do not accrue all the long-term benefits
of their investment because a fraction of members switch plans every year. A turnover rate of
12% was assumed for insurance membership i.e. 12% of individuals move to other insurance
plans each year [19].
Second, the main source of benefit is the premium income stream, which is independent of
the health status of the beneficiary (except in the case of death status). We considered average
insurance premiums from private individual health insurance plans when members were 57–
64 years old. When they turned 65, they were assumed to be in a Medicare Advantage plan.
Economic Evaluation of PCSK9 Inhibitors
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Table 1. Model Parameters.
Input Variable Parameter (Range or S.E.) Source
Rates and Probabilities
1-year probability of CVD event
From Framingham study
MI 0.14%-1.16% (age dependent) D’Agostino et al.
Stroke 0.08%-0.63% (age dependent) D’Agostino et al.
Other CVD 0.23%-1.65% (age dependent) D’Agostino et al.
From Sabatine et al. study
MI 0.30%-1.68% (age dependent) Sabatine et al.
Stroke 0.05%-0.28% (age dependent) Sabatine et al.
Other CVD 0.25%-1.40% (age dependent) Sabatine et al.
1-year probability of sub-sequent CVD event
MI 0.48%-1.86% (age dependent) D’Agostino et al.
Stroke 0.32%-1.02% (age dependent) D’Agostino et al.
Other CVD 0.93%-2.83% (age dependent) D’Agostino et al.
Mortality rates
After MI 8.2%-98.5% (age dependent) CDC
After Stroke 5.9%-93.4% (age dependent) CDC
After other CVD 7.0%-96.0% (age dependent) CDC
After post-MI 3.6%-67.3% (age dependent) Bronnun et al.
After post-Stroke 3.3%-60.9% (age dependent) Bronnun et al.
After post-other CVD 3.4%-64.1% (age dependent) Bronnun et al.
Non CVD related 0.5%-18.3% (age dependent) CDC
Costs
Statin treatment $48 ($36–$60) Erickson et al.
PCSK9 treatment $12,048 ($9,036–$15,060)
Baseline treatment $215 ($161–$269) Davis et al.
MI $11,071 ($8,303–$13,839) Erickson et al.
Post-MI $7,747 ($5,810–$9,684) Erickson et al.
Stroke $18,516 ($13,887–$23,145) Erickson et al.
Post-Stroke $7,770 ($5,828–$9,713) Erickson et al.
Other CVD $14,794 ($11,095–$18,492) Erickson et al.
Post–other CVD $7,759 ($5,819–$9,698) Erickson et al.
Utility
Statin/PCSK9 treatment 0.79 Sullivan at al.
MI (range over 5 years) 0.58–0.79 (0.54, 0.91) Sullivan at al.
Stroke (range over 5 years) 0.46–0.79 (0.52, 0.87) Sullivan at al.
Other CVD (range over 5 years) 0.63–0.79 (0.57, 0.96) Sullivan at al.
Dead 0
Health insurance parameters
Premium
Age
58–64 $223–$520 (age dependent) eHealth 2014
65+ $835 ($751.6, $1,043.9) CMS 2014
Deductible
Age
58–64 $3,882–$3,731 (age dependent) eHealth 2014
65+ $2,158 ($1,942.2, $2,697.5) CMS 2014
(Continued )
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We assumed a monthly premium of $520 for age 57–64 years old [20], and $835 for 65 or
older [21].
Third, private payer plans have a cost-sharing component. It was assumed the insurance
payer pays for therapy A or B after copayments and deductibles are paid by the patient. For
statins, payment coverage as a tier 1 drug and for PCSK9 inhibitors as a tier 2 drug was
assumed. No copayments/coinsurance for visits to providers were assumed. We considered
average insurance drug copayment and deductible from private individual health insurance
plans when individuals were 57–64 years. Drug monthly copayments were assumed at $11 for
statins and $31 for PCSK9, and an annual deductible of $3,731 was assumed for this age group
[22]. For individuals 65 years old or older, we considered average Medicare Advantage plan
cost-sharing. We assumed a drug monthly copayment of $5 for statins and $11 for PCSK9,
and an annual deductible of $2,158 for this age group [21].
The net present value (NPV) to the private payer was the avoided costs plus the insurance
premium less the cost of treatment, all at present values using a discount rate of 3%. Therefore,
the ROI is the NPV divided by the treatment cost. An ROI of less than zero would indicate a
net loss to the payer, while a ROI of greater than zero would indicates a net monetary gain to
the payer.
Costs
The cost of statin treatment (standard therapy) was assumed at $48 per year based on a low-
cost generic therapy [23,24]. The price of PCSK9 inhibitors was assumed at $14,000 per year
based on recent market reports [8]. Annual baseline treatment cost assumed one regular
office-based physician visit per year at $215 [25].
Costs of myocardial infarction and stroke are based on Medicare claims and clinical trial
studies, and they were obtained from Erikson and coauthors [23] as described in their techni-
cal appendix. The cost of myocardial infarction was assumed at $11,071 and at $7,647 the next
year after the event. Cost of stroke was assumed at $18,516 and at $7,770 the next year after the
event [23]. For years 2 to 5 after the CVD event, we assume a reduction of 25% in the cost from
previous year. For other CVDs, we took the average cost of myocardial infarction and stroke.
Uncertainty and Price Sensitivity Analysis
To account for the uncertainty in model parameters, an assumption was made about the prob-
ability distribution of costs, QALYs, insurance deductibles, copayments and premiums, and
transition probabilities of the Markov model. First, our baseline scenario for annual probabili-
ties of CVD events was changed. This alternative scenario was based on the 10-year
Table 1. (Continued)
Input Variable Parameter (Range or S.E.) Source
Tier 1
Age
58–64 11 (9.9, 13.75) eHealth 2014
65+ 5 (4.5, 6.25) CMS 2014
Tier 2
Age
58–64 31 (27.9, 38.75) eHealth 2014
65+ 11 (9.9, 13.75) CMS 2014
Turnover rate 12.20% (0.71%) Cutler et al.
doi:10.1371/journal.pone.0169761.t001
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Framingham risk equation [17] evaluated for the average patient from the evolocumab study.
In this scenario, annual probabilities of CVD events were obtained indirectly by imputing the
changes in LDL cholesterol reported by the evolocumab study (61% reduction in LDL level)
into the Framingham equation.
Second, a sensitivity analysis to price variability was proposed to PCSK9 inhibitors. Different
scenarios of PCSK9 inhibitor prices ranging from $500 to $15,000 a year were considered. For
each PCSK9 inhibitor price scenario, 1,000 independent Monte Carlo simulations of costs and
QALYs based on the probability distribution assumptions were drawn. Costs and QALYs were
drawn from a beta distribution, insurance turnover rate was draw from a normal distribution.
Probabilities of CVD and subsequent CVD events were drawn for each coefficient of the corre-
sponding risk equation, assuming a normal distribution. An ICER was obtained for each simu-
lation, and all ICERs were compared to thresholds to produce acceptability curves [26] for each
price scenario. For the health system perspective, each ICER was compared to willingness-to-
pay thresholds of $20,000, $50,000 and $100,000 for each additional QALY gained.
In further analyses, the acceptability of different price scenarios from the health system and
the private insurance payer perspectives was obtained. From a payer perspective, the accept-
ability is given by the probability of a positive ROI at each price level. All results are presented
in the form of acceptability curves.
Results
CEA and ROI Analysis
Table 2 presents the overall cost increase, compared to standard therapy, of PCSK9 inhibitors
at $14,000 and $15,000 annual price. It also shows the avoided costs or savings due to reduced
CVD events. Treatment and avoided costs are from the health system’s and payer’s perspec-
tive. Payer’s premium revenues are also presented as well as overall changes in QALYs, life-
years, and CVD events.
Table 3 summarizes the ICER and ROI results across different price scenarios. The current
$14,000 price point yields an ICER of $348,807 per QALY. Considering the highest willing-
ness-to-pay threshold of $100,000 per QALY, then PCSK9 is cost-effective from a health sys-
tem perspective only if the price is less than or equal to $4,250. However, at the cost-effective
Table 2. Incremental Costs, Revenues and Outcomes with PCSK9 (Per Patient. Health System’s and
Payer’s Perspective) 1/.
Perspective
Health System Payer 2/
Treatment cost (If price = $14,000) $237,718 $73,137
Treatment cost (if price = $15,000) $254,695 $78,463
Avoided cost (savings) -$5,800 -$1,095
Premium revenue $644
QALY 0.66
Life years 0.88
CVD events -0.41
1/ Effect of PCSK9 on annual probability of CVD is obtained directly from the 1 year effect study of
evolocumab.
2/ Private insurance perspective assuming national average premiums, medication copayments and
deductibles. It also includes a health insurance turnover rate of 12%.
All costs, revenues and outcomes are per patient and discounted at 3% discount rate.
doi:10.1371/journal.pone.0169761.t002
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price of around $4,250, PCSK9 is still not financially viable for private insurers, since they face
losses of $19,506 per treated patient, equivalent to a -91.8% ROI. PCSK9 is only financially via-
ble for payers (and health system) at a price of around $600 per year.
Uncertainty and Price Sensitivity Analysis
Changing our scenario of the effect of PCSK9 inhibitors on the one year relative risk reduction
in CVD events affects the cost-effectiveness and ROI results. When the reduction in CVD
events are obtained through the 10-year Framingham risk equation, PCSK9 inhibitors become
less cost-effective and less profitable to private insurers. Under this alternative scenario, the
$14,000 price point yields an ICER of $617,542 per QALY, and losses to private insurers of
$72,504 per patient (see S1 Appendix).
Acceptability curves under baseline scat different price scenarios are shown in Fig 2. For a
willingness-to-pay threshold of $100,000 per QALY, a PCSK9 inhibitor therapy priced at
$2,500 per year will be cost-effective about 99.8% of the time. A price of $5,000 will be cost-
effective 38% of the time, and a price of $7,500 will be cost-effective 4% of the time. At the cur-
rent market price of $14,000, there is a zero probability of PCSK9 inhibitors being cost-
effective.
Acceptability of PCSK9 inhibitors from private and health system perspective at different
PCSK9 inhibitors price scenarios is presented in Fig 3. The figure represents the probability
that PCSK9 inhibitor treatment adds value to the health system and an average private payer,
at different PCSK9 prices. At a price of $2,500 a year, a PCSK9 inhibitor has a high probability
of being cost-effective from a health system perspective (99.8% at a willingness-to-pay thresh-
old of $100,000 per QALY and 49.3% at $50,000 per QALY). However, at that same price of
Table 3. CEA and ROI analysis at Different Prices of PCSK9 (Health System’s and Payer’s Perspec-
tive) 1/.
PCSK9 inhibitor price Perspective
Health System Payer 2/
ICER ROI NPV
$500 $4,103 39.8% $495
$1,000 $16,870 -55.5% -$2,167
$2,500 $55,170 -85.4% -$10,156
$5,000 $119,004 -93.1% -$23,469
$7,500 $182,838 -95.5% -$36,783
$10,000 $246,673 -96.6% -$50,096
$12,500 $310,507 -97.3% -$63,410
$14,000 $348,807 -97.6% -$71,398
$15,000 $374,341 -97.8% -$76,723
Breakeven prices
$593 $6,478 0.0% $0
$4,256 $100,000 -91.8% -$19,506
1/ Effect of PCSK9 inhibitors on annual probability of CVD is obtained directly from the 1 year effect study of
evolocumab.
2/ Private insurance perspective assuming national average premiums, medication copayments and
deductibles. It also includes a health insurance turnover rate of 12%.
ICER = Incremental cost-effectiveness ratio. ROI = Return on investment. NPV = Net present value.
doi:10.1371/journal.pone.0169761.t003
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$2,500, the probability that an average private payer obtains a positive ROI is nearly zero. Only
at a price around $600 or less the average private payer would break even.
Discussion
Our study results suggest that from a health system perspective, PCSK9 inhibitors are not cost-
effective at current prices. At the current $14,000 to $15,000 price, the incremental cost per
additional QALY produced is nearly three and a half times the usual societal acceptable
$100,000 threshold. Moreover, our study finds that PCSK9 inhibitors are not financially viable
for an average private insurance payer. The ROI analysis, relevant for the U.S. multipayer
insurance market, suggests that the price of PCSK9 inhibitors would have to receive large dis-
counts to be a financially sound investment for insurers. Without price reductions, insurers
would have to recover the losses of covering these drugs by charging higher premiums.
Fig 2. Acceptability curve from health system perspective.
doi:10.1371/journal.pone.0169761.g002
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Because insurers can no longer charge higher premiums to individuals with chronic health
conditions under the terms of the Affordable Care Act, this burden would be spread over all
insured patients. However, it is unlikely that this cost would be fully transferred to premiums
given the rate-review provisions in the Affordable Care Act, which may result in increased bar-
riers to accessing these new drugs.
While robust LDL reduction has been established with the novel PCSK9 inhibitors, out-
come benefits of PCSK9 inhibitors have not yet been documented [1,5,27]. Under the assump-
tion of maximal improvement in CVD of 49.2% relative risk reduction based on the open label
studies, our results reveal that at current prices, PCSK9 inhibitors are unlikely to be cost-effec-
tive from a health system perspective nor profitable for insurers. At the current price of
$14,000 to $15,000, for every dollar invested, private insurers lose $1.98. For insurers to break-
Fig 3. Acceptability from private and health system perspective.
doi:10.1371/journal.pone.0169761.g003
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even, the price would have to fall to $600. To be cost-effective from a health system perspective,
the price would have to be reduced to $4,250.
Our results from a health system perspective compare to two recent CEA of PCSK9 inhibi-
tors. The Institute for Clinical and Economic Review estimated an ICER of $503,000 per
QALY [9–11], which is higher than our baseline estimate. Contrarily, researchers from
Amgen, producer of the PCSK9 inhibitor Repatha (evolocumab), estimated an ICER of
$75,800 per QALY [12], which is lower than our baseline estimate. The main reason explaining
the large difference in ICER estimates is the assumption in the dose-response between LDL
cholesterol and CVD events. In sensitivity analyses conducted to account for uncertainty in
the study parameters, drug prices, and societal willingness-to-pay for QALY improvements,
we observed cost-effectiveness and ROI to be highly sensitive to assumptions about the effect
of PCSK9 inhibitors on CVD events. All savings associated to PCSK9 inhibitors are the result
of avoided CVD events and mortality in the future. From a modelling point of view, reductions
in LDL cholesterol add value only if they are able to reduce CVD events. Since evidence about
the efficacy in reducing CVD events is mixed and still inconclusive in the long-run [6], this
assumption represents the major limitation of economic evaluation studies of PCSK9 inhibi-
tors. To incorporate the uncertainty of this parameter, we not only performed a sensitivity
analysis, but also considered an alternative scenario for the dose-response assumption between
LDL cholesterol and CVD events. Our baseline scenario combined the evolocumab study
results with the 10-year Framingham risk equation to estimate the long-run effect on CVD
events, which allows for a more realistic age-dependent dose-response between cholesterol lev-
els and CVD events. Our alternative scenario related LDL cholesterol levels with CVD events
through the Framingham risk equation, producing an ICER of $617,542 per QALY. Overall,
our results from a health system perspective coincide with the Institute for Clinical and Eco-
nomic Review’s conclusion that PCSK9 inhibitors are not cost-effective at current prices.
Our main limitation is that the effects of PCSK9 inhibitors on CVD outcomes are not yet
know. Studies are still limited to one-year randomized trials, and they are silent to long-run
effects. Although we reduced this limitation by considering two scenarios for annual probabili-
ties of CVD events in the long-run, our results are still limited to the lack of actual data on
effectiveness. As with any other decision analytic model, our methodology is also limited to
the simplifying assumptions about the underlying cohort characteristics used in analysis,
which do not represent the U.S. population. This study applies to a hypothetical population
that resembles the participants in the evolocumab PCSK9 study. What we lose in terms of rep-
resenting a larger population, we gain in terms of more accurate assumptions for the specific
cohort. We share the limitations of CEA, an incomplete tool that does not incorporates all of a
drug’s salient characteristics [28].
In conclusion, our study suggests that at current prices, PCSK9 inhibitors are unlikely to
add value to either the health system or private insurance payers. To be the breakthrough drug
in the fight against cardiovascular disease, the current price must be reduced to make PCSK9
inhibitors cost-effective to the health system and financially viable to payers. Our study also
finds an important gap between the price at which PCSK9 inhibitors become cost-effective
and the break-even price for private payers. This gap reflects the complexity of implementing a
value-based payment system in the U.S. healthcare market, and the challenges of aligning right
financial incentives for private payers to cover for cost-effective drugs. Because insurance com-
panies face all the investment cost but only a fraction of the long-term benefits, the payer’s pri-
vate value is generally lower than health system’s value. While payers can increase private
value by transferring the investment cost through higher cost-sharing to patients (for example,
listing PCSK9 inhibitors as tier 3 or 4 drugs), or higher premiums to all members, the current
high price of PCSK9 inhibitors and the provisions of the Affordable Care Act may limit these
Economic Evaluation of PCSK9 Inhibitors
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price transfer mechanisms. A major concern is that with limited price reduction or transferred
options, payers limit the access to the new drug. Given that the efficacy of PCSK9 inhibitors on
reducing CVD events is still inconclusive, and that ICER estimates are highly sensitive to this
assumption, limiting utilization of the drug may penalize a potential high-value health technol-
ogy [15]. A promising reimbursement strategy that is gaining attraction in the U.S. are out-
come-based contracts that tie price to patient outcomes. A recent survey from Avalere [29]
reports that a few insurance companies have entered in outcome-based contracts with produc-
ers of PCSK9 inhibitors in which they receive large discounts if LDL cholesterol reductions
among patients are lower than those observed in clinical trials. This type of outcome-based
reimbursement transfers some financial risk from payers to pharmaceutical companies, which
may help high-value drugs and benefit patients.
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